Tabuk Pharmaceuticals has entered into an exclusive licensing and supply agreement with red otc development GmbH for Ivy oro-dispersible thin films.

Under this agreement, red otc has granted Tabuk exclusive rights as the Marketing Authorization Holder for Ivy ODF, in order to commercialize and distribute Ivy ODF in Saudi Arabia. Ivy ODF contains herbal extract of the well-known plant Ivy. It’s the latest innovation in the field of herbal medicinal products – the first herbal medicinal product based on ODF technology in the world. The ODF technology is one of the most recommended dosage forms by the European Medicine Agency for the treatment of pediatric population and it offers many advantages compared to syrups. It provides the patient with the ease of use since it doesn’t need a measuring device, also it’s suitable for patients with swallowing impairments or having a high risk of aspiration. Moreover; its exact dosing; easy handling; “take-away” dosage form will give more convenient option for patients.

“Working exclusively together with Tabuk, a highly esteemed and leading pharmaceutical in middle east region, is a great honor for us. We are fully convinced that our partnership with Tabuk will be extremely fruitful for the future of both companies,” commented Dr. Thomas Haffner, general manager of red otc.